Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feng Zhan

Showing results (211-220 of 222) with videos related to

Pageof 23
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2021
Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort StudyJingge Qu, Mengtao Li, Yanhong Wang, et al.
Medcomm|November 17, 2025
Applying Genetic Risk Score to Improve Risk Assessment of New-Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large-Scale Prospective Cohort StudyYufang Ding, Mucong Li, Wei Bai, et al.
RMD Open|November 23, 2023
Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosusHanxiao You, Jiuliang Zhao, Miaojia Zhang, et al.
International Journal of Surgery (London, England)|September 24, 2025
Tophus severity grading and surgical treatment: Chinese medical doctor association multidisciplinary expert consensus statement and recommendations, 2025Yunchuan Pan, Shishuai Lin, Nanfang Pan, et al.
Clinical Rheumatology|June 21, 2014
The relationship between disease activity measured by the BASDAI and psychological status, stressful life events, and sleep quality in ankylosing spondylitisYutong Jiang, Mingcan Yang, Husheng Wu, et al.
Annals of the Rheumatic Diseases|February 7, 2025
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.
Annals of the Rheumatic Diseases|November 27, 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.
Thoracic Cancer|September 19, 2017
Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancerYan Sun, Jin Wan Wang, Yong Yu Liu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 13, 2025
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III TrialXu Liu, Liling Xu, Cheng Zhao, et al.
Frontiers in Immunology|September 29, 2022
A clinical practice guideline for the screening and assessment of enthesitis in patients with spondyloarthritisXinyu Wu, Dong Liu, Yanfei Li, et al.
Pageof 23

Showing results (211-220 of 222) with videos related to

Sort By:
Pageof 23
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2021
Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort StudyJingge Qu, Mengtao Li, Yanhong Wang, et al.
Medcomm|November 17, 2025
Applying Genetic Risk Score to Improve Risk Assessment of New-Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large-Scale Prospective Cohort StudyYufang Ding, Mucong Li, Wei Bai, et al.
RMD Open|November 23, 2023
Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosusHanxiao You, Jiuliang Zhao, Miaojia Zhang, et al.
International Journal of Surgery (London, England)|September 24, 2025
Tophus severity grading and surgical treatment: Chinese medical doctor association multidisciplinary expert consensus statement and recommendations, 2025Yunchuan Pan, Shishuai Lin, Nanfang Pan, et al.
Clinical Rheumatology|June 21, 2014
The relationship between disease activity measured by the BASDAI and psychological status, stressful life events, and sleep quality in ankylosing spondylitisYutong Jiang, Mingcan Yang, Husheng Wu, et al.
Annals of the Rheumatic Diseases|February 7, 2025
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.
Annals of the Rheumatic Diseases|November 27, 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.
Thoracic Cancer|September 19, 2017
Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancerYan Sun, Jin Wan Wang, Yong Yu Liu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 13, 2025
Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients with Active Ankylosing Spondylitis: Results from an Adaptive Seamless Phase II/III TrialXu Liu, Liling Xu, Cheng Zhao, et al.
Frontiers in Immunology|September 29, 2022
A clinical practice guideline for the screening and assessment of enthesitis in patients with spondyloarthritisXinyu Wu, Dong Liu, Yanfei Li, et al.
Pageof 23